Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents
32
This work was supported by the National Key R&D Program of China;the National Mega-project for Innovative Drugs of China;the National Natural Science Foundation of China;the National Science and Tech-nology Major Project;the Innova-tive Research Team of High-level Local Universities in Shanghai,the National Special Fund for State Key Laboratory of Bioreactor Engineering;the Shanghai Sailing Program;and the Shanghai Morning Light Program
2021-09-08(万方平台首次上网日期,不代表论文的发表时间)
共5页
1660-1664